Mesa Discusses What He’s Looking Forward to Most During 2022 in the Myelofibrosis Space


At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about clinical trials and treatments being utilized in 2022.

In 2022, we’re going to start to see some of these important phase 3 studies be reported out, and they’re going to be critically important. I’ve described it as if there’s multiple competing phase 3 clinical trials, what are those results and which patients benefit from which drug? How might we sequence them? How might we utilize them or compare them? I think this will become incredibly important. We will be considering what we anticipate with the use of a single-agent JAK2 inhibitors. Should everyone be on a combination? Should it be a subset or should we reverse switch to a second JAK2 inhibitor before we go to a combination? [There are many] questions. The data from the phase 3 studies are going to be incredibly important because although we have phase 2 data, they don’t really answer these questions. For the phase 3 data that are correlative studies, the long-term follow-up is going to be really important because we’ll have a range of options for treating folks. The differences that we learned from these data will help us make some of these decisions.

Recent Videos
Expert on MF
Experts on MF
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Ruben Mesa, MD, spoke about the approval of pacritinib and its importance for the treatment of myelofibrosis.